Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
aromatase inhibitor
Early switch to an aromatase inhibitor increases survival
By Dross at 2007-02-12 21:49
 

For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates, according to a new study. Published in the March 15, 2007 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study reveals that the clear survival benefit was also achieved without an increased risk of death from other causes,  a significant risk associated with tamoxifen. Hormone modulating therapies have made a significant impact on the survival rates of women with estrogen-sensitive breast cancer over the last two decades. The drugs are used as adjuvant to primary surgical treatment for a period of five years. Tamoxifen was the first estrogen modulator shown to increase survival and reduce the risk of breast cancer recurrence. However, tamoxifen is associated with increased risk of death from other causes, such as strokes and endometrial cancer.

read more | 6 comments | 2217 reads

Hormone drug type makes survival difference in advanced breast cancer
By Dross at 2007-01-31 05:03
 

 

Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies. In addition, aromatase inhibitors -- drugs known as Arimidex, Aromasin and Femara -- are less likely to cause blood clots and vaginal bleeding than other hormone treatments, said review co-author Judith Bliss of the Institute of Cancer Research in London. The review analyzed 30 studies involving the treatment of advanced breast cancer, encompassing more than 10,000 postmenopausal women. Bliss and colleagues were surprised at how few of the reviewed studies presented data on overall survival for women taking aromatase inhibitors.

read more | 2417 reads

Prostate Cancer Basics
By HCat at 2007-01-07 02:11

The Androgen Receptor

   The Androgen Receptor (AR) is a protein inside of certain cells that can bind or capture the androgen hormones testosterone and the more active metabolite 5alpha-dihydrotestosterone (DHT). Once the receptor binds one of the hormones, it causes the receptor to become active and stimulate production of certain proteins inside cells such as PSA.

It is known that AR is required for the normal development of the prostate. If a male animal has no AR, then the prostate will not be created of will be very small when he is born.

read more | 25711 reads

Breast cancer patients found to live longer with new drug :: Chron.com - Houston Chronicle
By admin at 2006-11-22 10:19
 

Switching patients with early breast cancer from a standard drug to a newer treatment helps them live longer and improves their odds of remaining free of the disease, German researchers said Friday.

Although tamoxifen has been the standard treatment following surgery for women with hormone sensitive tumors, they said changing to a newer class of drug called aromatase inhibitors improved overall survival. "A lot of people have been waiting to see whether aromatase inhibitors will show a survival advantage, and I think these data will assure them that five years of tamoxifen is no longer the standard of care ... ," said Walter Jonat, professor at the University of Kiel in Germany.

read more | 1793 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 02:34 AM.